Literature DB >> 11465950

Cytokines and malaria parasitemia.

J Jason1, L K Archibald, O C Nwanyanwu, M Bell, I Buchanan, J Larned, P N Kazembe, H Dobbie, B Parekh, M G Byrd, A Eick, A Han, W R Jarvis.   

Abstract

The balance between pro- and antiinflammatory cytokines may be important in malaria presentation and outcome. Malaria tends to be more severe in children than in adults, presumably because partial immunity develops with age. However, the full nature of, and age-related differences in, anti-malarial immunity are unknown. We compared: (1) serum and cell-specific cytokines of patients with acute malaria to those of patients with other acute illnesses and to those of healthy adults and (2) the cytokine responses of parasitemic children and parasitemic adults. Flow cytometry was done on the peripheral blood mononuclear cells of 148 hospitalized children, 161 febrile hospitalized adults, and 20 healthy adults in Malawi, Africa, a malaria-endemic country. Serum cytokines were also assessed for 80 of these patients. Thirty-eight participants were parasitemic with Plasmodium falciparum. Serum interleukin (IL)-10 (an antiinflammatory, immunoregulatory, and type 2 cytokine) levels were higher in malaria patients than in other patients (medians 502 pg/mL vs 16 pg/mL, P = 0.002), and the percentages of various lymphocyte populations making IL-6 (a proinflammatory, type 2 cytokine regulating iron distribution) were lower in malaria patients than in other patients (e.g., for spontaneous production by children's CD8(+) T cells: medians 1.4% vs 33.1%, P = 0.004). For adult patients, the percentages of lymphocytes spontaneously making IL-4 (a type 2 cytokine) were significantly lower in those with malaria than in those without malaria (medians 0.9% vs 2.1%, P = 0.005). The percentages of monocytes spontaneously making IL-8 (a chemotactic, proinflammatory chemokine) were higher in parasitemic children than in parasitemic adults (medians 5.8% vs 1.7%, P = 0.003). A number of cellular proinflammatory, type 1 parameters were significantly higher in all children (with or without malaria) than in all adults; these included the percentages of various lymphocyte populations making IL-6, both IL-6 and interferon-gamma, or IL-8. These data support the importance of IL-10 in malaria parasitemia. Given the lack of an IL-4 (type 2) response, IL-10's primary role may be immunoregulatory rather than type 2 in nature. In this study, the immune response to malaria was more proinflammatory in children than in adults. This difference, if corroborated by other studies, could be related to malaria's greater severity in children. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465950     DOI: 10.1006/clim.2001.5057

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  19 in total

1.  Protective vaccination alters gene expression of the liver of Balb/c mice in response to early prepatent blood-stage malaria of Plasmodium chabaudi.

Authors:  Saleh Al-Quraishy; Mohamed A Dkhil; Abdel Azeem S Abdel-Baki; Denis Delic; Frank Wunderlich
Journal:  Parasitol Res       Date:  2018-02-05       Impact factor: 2.289

2.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

3.  Comparison of serum and cell-specific cytokines in humans.

Authors:  J Jason; L K Archibald; O C Nwanyanwu; M G Byrd; P N Kazembe; H Dobbie; W R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Age-related differences in cell-specific cytokine production by acutely ill Malawian patients.

Authors:  J N Pettiford; J Jason; O C Nwanyanwu; L K Archibald; P N Kazembe; H Dobbie; W R Jarvis
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

5.  Vitamin A levels and immunity in humans.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Anne L Sowell; Ian Buchanan; Joshua Larned; Michael Bell; Peter N Kazembe; Hamish Dobbie; William R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

6.  Potential Role for Regulatory B Cells as a Major Source of Interleukin-10 in Spleen from Plasmodium chabaudi-Infected Mice.

Authors:  Xue Han; Ji Yang; Yitong Zhang; Yalin Zhang; Hongtao Cao; Yaming Cao; Zanmei Qi
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

7.  TREM-1 modulation produces positive outcome on the histopathology and cytokines release profile of Plasmodium berghei-infected mice.

Authors:  Voon Kin Chin; Afiq Mohd Yusof Asyran; Zainul Amiruddin Zakaria; Wan Omar Abdullah; Pei Pei Chong; Norshariza Nordin; Zaid Osamah Ibraheem; Roslaini Abdul Majid; Rusliza Basir
Journal:  J Parasit Dis       Date:  2018-12-15

8.  Spontaneous cytokine production and its effect on induced production.

Authors:  Derrick Walker; Janine Jason; Kelly Wallace; Justin Slaughter; Virginia Whatley; Alison Han; Okey C Nwanyanwu; Peter N Kazembe; Hamish Dobbie; Lennox Archibald; William R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production.

Authors:  Collins Ouma; Gregory C Davenport; Tom Were; Michael F Otieno; James B Hittner; John M Vulule; Jeremy Martinson; John M Ong'echa; Robert E Ferrell; Douglas J Perkins
Journal:  Hum Genet       Date:  2008-10-30       Impact factor: 4.132

10.  Protective Effect of Chronic Schistosomiasis in Baboons Coinfected with Schistosoma mansoni and Plasmodium knowlesi.

Authors:  Ruth K Nyakundi; Onkoba Nyamongo; Jeneby Maamun; Mercy Akinyi; Isaac Mulei; Idle O Farah; D'Arbra Blankenship; Brian Grimberg; Jann Hau; Indu Malhotra; Hastings Ozwara; Christopher L King; Thomas M Kariuki
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.